LFUS vs TGTX Comparison

Littelfuse is a primary provider of circuit protection products (such as fuses and relays) for the transportation, industrial, telecommunications, and consumer electronics end markets. The company is also increasing its power semiconductor business, where it predominantly serves industrial end markets, and is breaking into electric vehicle charging infrastructure. Littelfuse has 17,000 global employees.

TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.